Abstract
Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.
| Original language | English (US) |
|---|---|
| Journal | The Lancet Oncology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
}
Recommendations for management of patients with neuroendocrine liver metastases. / Frilling, Andrea; Modlin, Irvin M.; Kidd, Mark; Russell, Christopher; Breitenstein, Stefan; Salem, Riad; Kwekkeboom, Dik; Lau, Wan yee; Klersy, Catherine; Vilgrain, Valerie; Davidson, Brian; Siegler, Mark; Caplin, Martyn; Solcia, Enrico; Schilsky, Richard.
In: The Lancet Oncology, Vol. 15, No. 1, 01.01.2014.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Recommendations for management of patients with neuroendocrine liver metastases
AU - Frilling, Andrea
AU - Modlin, Irvin M.
AU - Kidd, Mark
AU - Russell, Christopher
AU - Breitenstein, Stefan
AU - Salem, Riad
AU - Kwekkeboom, Dik
AU - Lau, Wan yee
AU - Klersy, Catherine
AU - Vilgrain, Valerie
AU - Davidson, Brian
AU - Siegler, Mark
AU - Caplin, Martyn
AU - Solcia, Enrico
AU - Schilsky, Richard
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.
AB - Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.
UR - http://www.scopus.com/inward/record.url?scp=84891369262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891369262&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(13)70362-0
DO - 10.1016/S1470-2045(13)70362-0
M3 - Review article
AN - SCOPUS:84891369262
VL - 15
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 1
ER -